Investors

Press Releases

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

October 11, 2019

Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…

Read more

ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

October 9, 2019

Geneva, Switzerland and Boston, MA – October 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss  clinical-stage…

Read more

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

September 27, 2019

Geneva, Switzerland and Boston, MA – September 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva announces new composition of its Executive Committee

September 11, 2019

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more

ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

September 3, 2019

Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

August 30, 2019

Geneva, Switzerland and Boston, MA – August 30, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13- 14, 2019

August 9, 2019

Geneva, Switzerland and Boston, MA – August 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

August 7, 2019

Geneva, Switzerland and Boston, MA – August 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more

ObsEva Reports Second Quarter 2019 Financial Results

August 7, 2019

    Multiple Major Milestones Expected This Year Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban Nolasiban MAA…

Read more

ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019

August 5, 2019

Geneva, Switzerland and Boston, MA – August 5, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.